Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy

This publication has 43 references indexed in Scilit:

• Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis
  Transplantation and Cellular Therapy, 2022
• Land(mark) ahoy: PFS24 in relapsed/refractory diffuse large B-cell lymphoma
  Transplantation and Cellular Therapy, 2022
• Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma
  Transplantation and Cellular Therapy, 2022
• Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma
  Transplantation and Cellular Therapy, 2022
• Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
  The Lancet, 2020
• Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies
  Cancer Treatment Reviews, 2020
• Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies
  American Journal of Hematology, 2016
• Non‐Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011
  American Journal of Hematology, 2015
• Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation
  Transplantation and Cellular Therapy, 2014
• A note on quantifying follow-up in studies of failure time
  Controlled Clinical Trials, 1996